SB-649868

DB14822InvestigationalSmall molecule

SB-649868 is under investigation in clinical trial NCT01030939 (Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers).

Mechanism: Pharmacologically active on Orexin/Hypocretin receptor type 1 and Orexin receptor type 2
Curator reviewed
Formula / weight: C₂₆H₂₄FN₃O₃S · 477.55 g/mol (avg)
Code names: SB-649868

Resolves to

Compound

UNII1L1V1K2M4VCAS380899-24-1ChEMBLCHEMBL1272307

Structure

InChIKeyZJXIUGNEAIHSBI-IBGZPJMESA-NSMILESCC1=NC(C(=O)N2CCCC[C@H]2CNC(=O)C2=CC=CC3=C2C=CO3)=C(S1)C1=CC=C(F)C=C1

Targets

O43613HCRTR1O43614HCRTR2

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with SB-649868, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account